Abstract
fSCIG (facilitated immune globulin infusion 10% [human] with recombinant human hyaluronidase [rHuPH20]) is a subcutaneously administered IG, approved for patients with primary immunodeficiency diseases (PIDD). The objective of this study was to acquire data from clinical practice on long-term safety of fSCIG in patients with PIDD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
